Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Merado v. AstraZeneca Pharmaceuticals LP et al
Case Number:
1:06-cv-00071
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
- AstraZeneca PLC
- Blue Cross Blue Shield of North Carolina
- Blue Cross of Northeastern Pennsylvania
- CVS Health Corp.
- Medical Mutual of Ohio
- Regence BlueCross BlueShield
- Rite Aid Corp.
- Safeway Inc.
- Supervalu Inc.
- The Kroger Co.
- United Food & Commercial Workers International Union
Sectors & Industries:
-
September 25, 2012
AstraZeneca To Pay $11M To Settle Toprol-XL Antitrust Claims
AstraZeneca Pharmaceuticals LP on Tuesday agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation to prolong a monopoly on the drug by delaying generic versions.
-
May 31, 2012
AstraZeneca To Settle Toprol-XL Antitrust Action
AstraZeneca Pharmaceuticals LP reached an agreement Wednesday to resolve claims brought in Delaware by a putative class of indirect purchasers of Toprol-XL who allege the pharmaceutical giant used sham patent litigation to delay generic competition for the hypertension drug.